OPR - Delayed Quote • USD CRDF Nov 2024 10.000 put (CRDF241115P00010000) Follow 5.20 0.00 (0.00%) As of April 4 at 3:52 PM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for CRDF241115P00010000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CRDF Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 Cardiff Oncology Full Year 2023 Earnings: Beats Expectations Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
